{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-029582","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.575364+00:00","generated_at":"2026-05-17T17:10:42.716576+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rocket Pharmaceuticals: President Patel to depart, 30% workforce cut, Q2 net loss $68.9M","bullets":["Dr. Kinnari Patel to leave as President and Head of R&D effective Dec 31, 2025; steps down Aug 8.","Workforce reduction of ~30% and cash burn cut ~25% as part of strategic restructuring.","Q2 net loss $68.9M ($0.62/share); cash $271.5M; expects runway into Q2 2027.","Clinical hold on RP-A501 Danon disease trial ongoing after patient death; engaging with FDA.","Chris Stevens appointed COO in July; former Spark Therapeutics executive."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-029582","json":"https://secwatch.observer/filing/0001140361-25-029582.json","markdown":"https://secwatch.observer/filing/0001140361-25-029582.md","text":"https://secwatch.observer/filing/0001140361-25-029582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/0001140361-25-029582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/ef20053509_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:10:42.716576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}